Medtronic plc MDT recently commenced the enrolment for a prospective, multicenter, global, post-market study of its InterStim Micro neurostimulator — Evaluation of InterStim Micro System Performance ...
Medtronic plc has won U.S. FDA approval of its Interstim Micro rechargeable sacral nerve stimulator and Interstim Surescan MRI leads for the treatment of urinary and bowel dysfunctions. The new ...
After receiving an FDA approval earlier this week for its newly miniaturized and rechargeable sacral nerve stimulator, Medtronic reported that its first patient has received the implant through the ...
Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI ...
The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation systems that use SureScan MRI leads, enabling a broader range of MRI scan parameters, ...
Medtronic plc today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio’s recharge-free device – and it ...
DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...
DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Medtronic plc MDT, the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback